Ono Pharmaceutical Co., Ltd. (TYO:4528)
1,501.00
-46.00 (-2.97%)
May 14, 2025, 3:30 PM JST
Ono Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Revenue | 486,871 | 502,672 | 447,187 | 361,361 | 309,284 | Upgrade
|
Revenue Growth (YoY) | -3.14% | 12.41% | 23.75% | 16.84% | 5.77% | Upgrade
|
Cost of Revenue | 147,950 | 127,126 | 110,062 | 93,511 | 85,573 | Upgrade
|
Gross Profit | 338,921 | 375,546 | 337,125 | 267,850 | 223,711 | Upgrade
|
Selling, General & Admin | 122,289 | 97,389 | 86,643 | 74,119 | 66,616 | Upgrade
|
Research & Development | 149,866 | 112,174 | 95,344 | 75,879 | 62,384 | Upgrade
|
Other Operating Expenses | 3,636 | 2,807 | 2,250 | 4,099 | -6,626 | Upgrade
|
Operating Expenses | 275,791 | 215,251 | 187,080 | 157,035 | 124,988 | Upgrade
|
Operating Income | 63,130 | 160,295 | 150,045 | 110,815 | 98,723 | Upgrade
|
Interest Expense | -5,318 | -125 | -89 | -84 | -105 | Upgrade
|
Interest & Investment Income | 4,774 | 3,574 | 2,403 | 2,349 | 2,462 | Upgrade
|
Earnings From Equity Investments | 125 | 1 | 4 | -6 | 4 | Upgrade
|
Currency Exchange Gain (Loss) | - | 347 | -723 | -425 | 4 | Upgrade
|
Other Non Operating Income (Expenses) | - | 235 | 182 | 399 | 72 | Upgrade
|
EBT Excluding Unusual Items | 62,711 | 164,327 | 151,822 | 113,048 | 101,160 | Upgrade
|
Merger & Restructuring Charges | -3,382 | - | - | - | - | Upgrade
|
Gain (Loss) on Sale of Investments | - | -92 | -46 | -116 | 122 | Upgrade
|
Gain (Loss) on Sale of Assets | - | -118 | -94 | -64 | -7 | Upgrade
|
Asset Writedown | - | -51 | -498 | -316 | -2 | Upgrade
|
Legal Settlements | - | -333 | -7,652 | -7,527 | -384 | Upgrade
|
Pretax Income | 59,329 | 163,733 | 143,532 | 105,025 | 100,889 | Upgrade
|
Income Tax Expense | 9,163 | 35,694 | 30,619 | 24,340 | 25,392 | Upgrade
|
Earnings From Continuing Operations | 50,166 | 128,039 | 112,913 | 80,685 | 75,497 | Upgrade
|
Minority Interest in Earnings | -119 | -62 | -190 | -166 | -72 | Upgrade
|
Net Income | 50,047 | 127,977 | 112,723 | 80,519 | 75,425 | Upgrade
|
Net Income to Common | 50,047 | 127,977 | 112,723 | 80,519 | 75,425 | Upgrade
|
Net Income Growth | -60.89% | 13.53% | 40.00% | 6.75% | 26.33% | Upgrade
|
Shares Outstanding (Basic) | 470 | 480 | 488 | 496 | 499 | Upgrade
|
Shares Outstanding (Diluted) | 470 | 480 | 488 | 497 | 499 | Upgrade
|
Shares Change (YoY) | -2.14% | -1.70% | -1.65% | -0.54% | -0.96% | Upgrade
|
EPS (Basic) | 106.55 | 266.61 | 230.85 | 162.19 | 151.11 | Upgrade
|
EPS (Diluted) | 106.41 | 266.57 | 230.79 | 162.16 | 151.09 | Upgrade
|
EPS Growth | -60.08% | 15.50% | 42.32% | 7.33% | 27.56% | Upgrade
|
Free Cash Flow | 77,028 | 106,640 | 154,270 | 56,332 | 66,959 | Upgrade
|
Free Cash Flow Per Share | 163.97 | 222.15 | 315.90 | 113.45 | 134.13 | Upgrade
|
Dividend Per Share | 80.000 | 80.000 | 70.000 | 56.000 | 50.000 | Upgrade
|
Dividend Growth | - | 14.29% | 25.00% | 12.00% | 11.11% | Upgrade
|
Gross Margin | 69.61% | 74.71% | 75.39% | 74.12% | 72.33% | Upgrade
|
Operating Margin | 12.97% | 31.89% | 33.55% | 30.67% | 31.92% | Upgrade
|
Profit Margin | 10.28% | 25.46% | 25.21% | 22.28% | 24.39% | Upgrade
|
Free Cash Flow Margin | 15.82% | 21.21% | 34.50% | 15.59% | 21.65% | Upgrade
|
EBITDA | 90,024 | 178,435 | 167,496 | 128,536 | 114,543 | Upgrade
|
EBITDA Margin | 18.49% | 35.50% | 37.45% | 35.57% | 37.04% | Upgrade
|
D&A For EBITDA | 26,894 | 18,140 | 17,451 | 17,721 | 15,820 | Upgrade
|
EBIT | 63,130 | 160,295 | 150,045 | 110,815 | 98,723 | Upgrade
|
EBIT Margin | 12.97% | 31.89% | 33.55% | 30.67% | 31.92% | Upgrade
|
Effective Tax Rate | 15.44% | 21.80% | 21.33% | 23.18% | 25.17% | Upgrade
|
Advertising Expenses | - | 24,019 | 17,837 | 11,496 | 6,903 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.